In this investigation, we analyzed peripheral blood mononuclear cells (PBMCs) before and after treatment in individuals with advanced HER2‐negative breast cancer undergoing anti‐PD‐1 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.